Pipeline
We are an unparalleled biopharmaceutical company.
Novel Drugs
- AP20Preclinical
-
Primary TargetUndisclosed
PlatformBispecific Receptor-Fc Conjugate
IndicationOsteoarthritis
- AP40Preclinical
-
Primary TargetCA12
PlatformFc Engineered Antibody
IndicationTriple Negative Breast Cancer (TNBC)
- AP70Discovery
-
Primary TargetCD47
PlatformBispecific Antibody
IndicationAcute Myeloid Leukemia
- AP10Discovery
-
Primary TargetCD43
PlatformBispecific Antibody
IndicationBlood & Solid Cancer
- AP60Discovery
-
Primary TargetTag72
PlatformBispecific Antibody
IndicationColorectal Cancer
- About Us Privacy Policy Inquiries Sitemap
-
Company Infomation
Aprogen
545, Dunchon-daero, Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea, 13215
Contact : +82-31-625-4045
-
Aprogen
545, Dunchon-daero, Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea, 13215
Contact : +82-31-625-4045 - copyright(c) by APROGEN. All Right Reserved.